Abstract |
Initial clinical investigations on tazarotene, a new acetylenic retinoid, have suggested potential usefulness in the treatment of mild-to-moderate plaque psoriasis. Tazarotene promotes healing of psoriatic lesions by modulating the key pathogenetic factors in this disease. It is not sensitizing, phototoxic, or photoallergenic, but causes moderate dose-related skin irritation. Systemic absorption is minimal and elimination is rapid, providing a low potential for systemic adverse effects. Tazarotene effectively treats mild-to-moderate plaque-type psoriasis, the benefits seem to be sustained after the cessation of therapy, and once-daily treatment is equally effective as more frequent application.
|
Authors | R Marks |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 135 Suppl 49
Pg. 26-31
(Oct 1996)
ISSN: 0007-0963 [Print] England |
PMID | 9035702
(Publication Type: Journal Article)
|
Chemical References |
- Gels
- Nicotinic Acids
- Teratogens
- tazarotene
|
Topics |
- Clinical Trials as Topic
- Gels
- Humans
- Nicotinic Acids
(therapeutic use)
- Psoriasis
(drug therapy, pathology)
- Randomized Controlled Trials as Topic
- Skin
(drug effects, pathology)
- Teratogens
(pharmacology)
|